- Home
- HPP vs STOK Comparison
HPP vs STOK Comparison
Compare HPP & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPP
- STOK
- Stock Information
- Founded
- HPP 2009
- STOK 2014
- Country
- HPP United States
- STOK United States
- Employees
- HPP N/A
- STOK N/A
- Industry
- HPP Real Estate
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- HPP Finance
- STOK Health Care
- Exchange
- HPP Nasdaq
- STOK Nasdaq
- Market Cap
- HPP 660.6M
- STOK 721.4M
- IPO Year
- HPP 2010
- STOK 2019
- Fundamental
- Price
- HPP $3.06
- STOK $11.27
- Analyst Decision
- HPP Hold
- STOK Strong Buy
- Analyst Count
- HPP 11
- STOK 7
- Target Price
- HPP $5.95
- STOK $21.40
- AVG Volume (30 Days)
- HPP 2.7M
- STOK 460.7K
- Earning Date
- HPP 11-12-2024
- STOK 11-05-2024
- Dividend Yield
- HPP 6.53%
- STOK N/A
- EPS Growth
- HPP N/A
- STOK N/A
- EPS
- HPP N/A
- STOK N/A
- Revenue
- HPP $847,713,000.00
- STOK $16,742,999.00
- Revenue This Year
- HPP N/A
- STOK $91.67
- Revenue Next Year
- HPP $2.73
- STOK $5.45
- P/E Ratio
- HPP N/A
- STOK N/A
- Revenue Growth
- HPP N/A
- STOK 81.08
- 52 Week Low
- HPP $3.05
- STOK $3.77
- 52 Week High
- HPP $9.86
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- HPP 24.07
- STOK 33.56
- Support Level
- HPP $4.04
- STOK $11.08
- Resistance Level
- HPP $4.51
- STOK $14.72
- Average True Range (ATR)
- HPP 0.26
- STOK 0.75
- MACD
- HPP -0.12
- STOK -0.23
- Stochastic Oscillator
- HPP 0.92
- STOK 5.22
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.